Fig. 7
From: Stem cell phenotype predicts therapeutic response in glioblastomas with MGMT promoter methylation
Stratification by SOX2 expression reveals that MGMT promoter methylation is a predictor of progression-free survival (PFS) and overall survival (OS) only in patients with high SOX2 (Raw score > 100) expression in Kaplan–Meier analysis. In patients with low SOX2 expression (Raw score ≤ 100), there was no-significant difference in survival between those with methylated MGMT and those with unmethylated MGMT. (Methylated, green, Unmethylated, blue N = number of patients at time 0, Med = median survival in months)